On January 24, 2025, subsidiaries of China Medical System Holdings Limited (China Medical System) signed a cooperation agreement with Hunan Mabgeek Biotechnology Co., Ltd. (Mabgeek Biotech) and its subsidiaries for the innovative Class 1 drug anti-IL-4Rα humanized monoclonal antibody injection MG-K10. The agreement grants rights for the co-development and exclusive commercialization of the product in mainland China, Hong Kong SAR, Macau SAR, Taiwan and Singapore (‘Regions’). Mabgeek Biotech will support commercialization activities and handle the sales and supply of the product. The cooperation term is perpetual.

IL-4Rα is considered a key target for treating type 2 inflammatory diseases such as atopic dermatitis (AD), asthma and nodular prurigo. Anti-IL-4Rα monoclonal antibodies are currently among the best-selling biologics in the field of type 2 inflammatory diseases. The cooperative product MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory factors IL-4 and IL-13. Following Fc mutation, MG-K10 reduces dosing frequency owing to its prolonged half-life, potentially becoming the first long-acting anti-IL-4Rα monoclonal antibody marketed domestically. Existing anti-IL-4Rα drugs require bi-weekly dosing, while MG-K10 only requires dosing every four weeks, demonstrating good efficacy and safety with the potential to become best-in-class (BIC).

JunHe was entrusted by Mabgeek Biotech to review, amend and negotiate the transaction documents. Throughout the transaction process, JunHe provided professional, efficient and meticulous legal services, earning the trust and recognition of the client.

The project was led by partner Mr. ZHAO, Hao (Gerry), with significant assistance from Mr. ZHOU, Feng (Frank).